Evidence map›Paper›PMID 40863969›Full record

ReviewToxics2025

New Horizons in Skin Sensitization Assessment of Complex Mixtures: The Use of New Approach Methodologies Beyond Regulatory Approaches.

Argel Islas-Robles, Meera Ramani, Jakeb Phillips, Gertrude-Emilia Costin

Abstract readReview
In one paragraph

Review in Toxics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Argel Islas-RoblesDepartment of Skin Sensitization, Institute for In Vitro Sciences, Inc. (IIVS), Gaithersburg, MD 20878, USA.ORCID 0000-0003-3611-2314
Meera RamaniDepartment of Skin Sensitization, Institute for In Vitro Sciences, Inc. (IIVS), Gaithersburg, MD 20878, USA.ORCID 0000-0003-0680-8572
Jakeb PhillipsDepartment of Skin Sensitization, Institute for In Vitro Sciences, Inc. (IIVS), Gaithersburg, MD 20878, USA.ORCID 0009-0001-1614-3204
Gertrude-Emilia CostinDepartment of Skin Sensitization, Institute for In Vitro Sciences, Inc. (IIVS), Gaithersburg, MD 20878, USA.ORCID 0000-0002-9514-0334

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Skin sensitization is a complex biological process induced by a wide range of chemicals, from single molecules to complex mixtures and finished products. While single chemical entities were used to design and validate sophisticated safety assessment assays, complex chemistries have proven challenging to test in practice using these methods. These assays range from in silico and in chemico methods to cell-based and reconstructed tissues-based approaches and target the key events now grouped within the Adverse Outcome Pathway. We focused our analysis on the use of New Approach Methodologies for skin sensitization assessments of complex mixtures, botanicals, medical and wearable devices, agrochemicals, and pollutants. We present the defined approaches that integrate these technologies, aligning with the principles of the replacement, reduction, and refinement of animal testing. We also detail the known challenges posed by these product classes in terms of testing and data interpretation. Our analysis indicates that validated and non-validated NAMs have shown some success in predicting skin sensitization potential across the product categories reviewed.

Indexed as

allergic contact dermatitisbotanicalsextractsin chemicoin silicoin vitromedical devicesmixturesNew Approach Methodologies (NAMs)pollutantsskin sensitizationwearables

Identifiers

PMID40863969
PMCPMC12390330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.